Automated Author ProfileWinzeler, Bettina
Winzeler, Bettina
Current S-Index
Sum of Dataset Indices for all datasets
Average Dataset Index per Dataset
Average Dataset Index per dataset
Total Datasets
Total datasets for this author
Average FAIR Score
Average FAIR Score per dataset
Total Citations
Total citations to the author's datasets
Total Mentions
Total mentions of the author's datasets
S-Index Interpretation
The S-Index (Sharing Index) is a comprehensive metric that represents the cumulative impact of all your datasets. It is calculated as the sum of Dataset Index scores across all your claimed datasets.
What it means:
- A higher S-index indicates greater overall impact of your datasets relative to typical datasets in their fields of research
- The S-Index grows as you add more datasets or as existing datasets gain more citations and mentions
- It provides a single number to track your research data impact over time
Current S-Index: 2.4 (sum of 4 datasets Dataset Index scores)
More information here.
S-Index Over Time
Cumulative Citations Over Time
Cumulative Mentions Over Time
Datasets
The syndrome of inappropriate antidiuresis (SIAD) is the main cause of hyponatremia and the SGLT2-inhibitor empagliflozin is a promising new treatment option. A biomarker predicting treatment response could optimize treatment success. Secondary analysis of a trial including 84 hospitalized patients with SIAD-induced hyponatremia. Patients were randomized to four days of treatment with empagliflozin 25 mg/d (n = 43) or placebo (n = 41) with both groups receiving fluid restriction <1000 ml/d. Baseline levels of copeptin, the natriuretic peptides MR-proANP and NT-proBNP and C-reactive protein (CRP) were evaluated as predictors for treatment response defined as absolute sodium change, using linear regression models. Additionally, urinary sodium was assessed as predictor for non-response to fluid restriction alone by constructing the receiver-operating characteristic (ROC) curve. No clinically relevant predictive value for treatment response to empagliflozin could be found for copeptin, MR-proANP, NT-proBNP or CRP. A urinary sodium cut-off of >76 mmol/l led to a specificity of 91.7% [95% confidence interval (CI): 75%, 100%] and sensitivity of 51.9% [33.3%, 70.4%] to predict non-response to fluid restriction alone. Based on our data, no biomarker could be identified as predictor for treatment response to empagliflozin. Urinary sodium was confirmed as a good marker for non-response to fluid restriction in SIAD patients. Clinical trial registration: ClinicalTrials.gov (Number: NCT02874807)
Authors
- Nobbenhuis, Rianne ;
- Refardt, Julie ;
- Vogt, Deborah ;
- Sailer, Clara O. ;
- Winzeler, Bettina ;
- Christ-Crain, Mirjam
The syndrome of inappropriate antidiuresis (SIAD) is the main cause of hyponatremia and the SGLT2-inhibitor empagliflozin is a promising new treatment option. A biomarker predicting treatment response could optimize treatment success. Secondary analysis of a trial including 84 hospitalized patients with SIAD-induced hyponatremia. Patients were randomized to four days of treatment with empagliflozin 25 mg/d (n = 43) or placebo (n = 41) with both groups receiving fluid restriction <1000 ml/d. Baseline levels of copeptin, the natriuretic peptides MR-proANP and NT-proBNP and C-reactive protein (CRP) were evaluated as predictors for treatment response defined as absolute sodium change, using linear regression models. Additionally, urinary sodium was assessed as predictor for non-response to fluid restriction alone by constructing the receiver-operating characteristic (ROC) curve. No clinically relevant predictive value for treatment response to empagliflozin could be found for copeptin, MR-proANP, NT-proBNP or CRP. A urinary sodium cut-off of >76 mmol/l led to a specificity of 91.7% [95% confidence interval (CI): 75%, 100%] and sensitivity of 51.9% [33.3%, 70.4%] to predict non-response to fluid restriction alone. Based on our data, no biomarker could be identified as predictor for treatment response to empagliflozin. Urinary sodium was confirmed as a good marker for non-response to fluid restriction in SIAD patients. Clinical trial registration: ClinicalTrials.gov (Number: NCT02874807)
Authors
- Nobbenhuis, Rianne ;
- Refardt, Julie ;
- Vogt, Deborah ;
- Sailer, Clara O. ;
- Winzeler, Bettina ;
- Christ-Crain, Mirjam
Spreadsheet of study data. (XLSX 57 kb)
Authors
- Blum, Claudine ;
- Winzeler, Bettina ;
- Nigro, Nicole ;
- Schuetz, Philipp ;
- Biethahn, Silke ;
- Kahles, Timo ;
- Mueller, Cornelia ;
- Timper, Katharina ;
- Haaf, Katharina ;
- Tepperberg, Janina ;
- Amort, Margareth ;
- Huber, Andreas ;
- Bingisser, Roland ;
- SĂĄndor, Peter ;
- Nedeltchev, Krassen ;
- MĂźller, Beat ;
- Katan, Mira ;
- Christ-Crain, Mirjam
Spreadsheet of study data. (XLSX 57 kb)
Authors
- Blum, Claudine ;
- Winzeler, Bettina ;
- Nigro, Nicole ;
- Schuetz, Philipp ;
- Biethahn, Silke ;
- Kahles, Timo ;
- Mueller, Cornelia ;
- Timper, Katharina ;
- Haaf, Katharina ;
- Tepperberg, Janina ;
- Amort, Margareth ;
- Huber, Andreas ;
- Bingisser, Roland ;
- SĂĄndor, Peter ;
- Nedeltchev, Krassen ;
- MĂźller, Beat ;
- Katan, Mira ;
- Christ-Crain, Mirjam